DCAKD (dephospho-CoA kinase domain containing) is a gene located on chromosome 17 that encodes a protein with dephospho-CoA kinase activity involved in coenzyme A biosynthesis 1. Based on Gene Ontology annotations, DCAKD localizes to the mitochondrial outer membrane and participates in CoA biosynthetic processes, suggesting a role in cellular energy metabolism and cofactor homeostasis. Clinically, DCAKD has emerged as a novel susceptibility gene for idiopathic inflammatory myopathies (IIMs, myositis), a group of rare autoimmune disorders causing muscle inflammation and weakness 1. Fine-mapping and expression quantitative trait locus colocalization analyses identified putative causal variants in DCAKD within skin and muscle tissues, indicating direct relevance to myositis pathogenesis 1. Additionally, DCAKD has been implicated in neurological contexts, with eQTL-derived expression scores showing associations with white matter microstructural integrity measures, and the gene appearing in analyses of neurodegenerative disease mechanisms including Parkinson's disease and Huntington's disease transitions 234. DCACKD was also identified as a marker gene in epigenome-wide methylation studies of COVID-19 patients, with differential methylation in its promoter region 5. These findings suggest DCAKD functions at the intersection of metabolic regulation and immune/neurological disease pathogenesis, though its precise molecular mechanisms in these contexts require further investigation.